Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is a key driver in non-small cell lung cancer (NSCLC) tumorigenesis.
• Targeting EGFR signaling is a validated therapeutic strategy for NSCLC.
• Identifying novel inhibitors of EGFR signaling is crucial for advancing NSCLC treatment.

Purpose of the Study:

• To investigate the potential of oxymatrine as an EGFR signaling pathway inhibitor in NSCLC.
• To evaluate the efficacy and safety of oxymatrine in NSCLC cell lines and a xenograft mouse model.

Main Methods:

• Screening of natural compounds for EGFR inhibitory activity.
• Assessment of oxymatrine's effects on NSCLC cell proliferation (anchorage-dependent and independent growth).
• Evaluation of oxymatrine's cytotoxicity in normal lung cells.
• Analysis of oxymatrine's impact on wild-type and mutated EGFR activity (exon 19 deletion, L858R/T790M).
• Flow cytometry to determine cell cycle effects and EGFR-Akt signaling dependency.
• Xenograft mouse model to assess in vivo tumor growth suppression.

Main Results:

• Oxymatrine identified as an EGFR signaling pathway inhibitor in NSCLC.
• Oxymatrine inhibited NSCLC cell growth but showed no cytotoxicity in normal lung cells.
• Oxymatrine suppressed wild-type, exon 19 deletion, and L858R/T790M mutated EGFR activation.
• Oxymatrine induced G0/G1 cell cycle arrest, dependent on EGFR-Akt signaling.
• Overexpression of Myr-Akt rescued cyclin D1 expression in HCC827 cells.
• Oxymatrine significantly suppressed tumor growth in a xenograft mouse model.

Conclusions:

• Oxymatrine is a potent inhibitor of EGFR signaling in NSCLC.
• Oxymatrine demonstrates anti-proliferative effects on NSCLC cells and suppresses tumor growth in vivo.
• Oxymatrine represents a potential novel therapeutic agent for NSCLC treatment, targeting various EGFR mutations.